Founded in 2016, today Indaco Venture Partners SGR is the largest independent Italian venture capital asset management company, with a strong specialization in companies that innovate in electronics and robotics, life science, digital and new materials.
Indaco manages over EUR 350 million across its six funds.
Investments in Indaco Ventures Fund I are focused on growth-stage companies whose competitive advantage stems from cutting-edge proprietary technologies and innovations. In terms of teams and technologies, the focus is on Italian enterprises, although investments are made throughout Europe, USA, Canada and Israel.
Indaco Bio Fund invests in the development of innovative and high-quality therapies. All therapeutic indications are covered with particular attention to Oncology, CNS, Ophthalmology, Metabolic diseases and Virology and Infectious diseases. Investments are focused on the Italian Biotech sector with select investments in other European countries, USA, Canada or Israel.
Anchor institutional investors in Indaco Ventures Fund I include Intesa Sanpaolo, Fondazione Cariplo, European Investment Fund, CDP Venture Capital SGR, Quaestio SGR and Inarcassa.
In the digital sector, Indaco has an advisory partnership with growITup and for Biotech and Pharma Indaco has a partnership with Università di Milano.
The investment team managers have an extensive experience in venture investing in Italy and abroad and have executed a high number of successful exits, including IPOs and transactions with corporate partners.
The management team owns 51% of Indaco Venture Partners SGR, Intesa Sanpaolo and Futura Invest (Fondazione Cariplo) are minority shareholders with 24,5% each.
Board of Directors:
Salvatore Bragantini – Chairman
Elizabeth Robinson – Vice Chairman
Davide Turco – Managing Director
Board of Statutory Auditors:
Federica Mantini – Chairman